4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no […]
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and genetic background. FSGS patients often progress to end-stage renal disease requiring dialysis and/or kidney transplantation, adding a significant socioeconomic burden to the individual burden of patients. There are approximately 140.000 patients with FSGS worldwide, qualifying […]